Market Overview:
The global glycopeptide antibiotics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of infectious diseases, rising demand for novel antibiotics, and growing investments by pharmaceutical companies in R&D for new glycopeptide antibiotics. Based on type, the global glycopeptide antibiotics market is segmented into vancomycin, teicoplanin, and bleomycin. Vancomycin is currently the most commonly used glycopeptide antibiotic and accounts for a major share of the global market. However, teicoplanin is expected to grow at a higher CAGR during the forecast period as it has several advantages over vancomycin such as better oral bioavailability and longer half-life. Bleomycin is used as an anticancer agent but also has antibacterial properties against certain types of bacteria such as Staphylococcus aureus and Enterococcus faecalis. Based on application, the global glycopeptide antibiotics market is segmented into enterococcus treatment, staphylococcus aureus treatment, pneumonias (pneumocystis carinii pneumonia (PCP) & bacterial pneumonia), other infections (urinary tract infection (UTI), skin infection & sepsis), and others (including prophylaxis).
Product Definition:
Glycopeptide antibiotics are a class of antibiotics that work by inhibiting the synthesis of peptidoglycan, which is an important component of the cell wall of bacteria. They are used to treat serious infections caused by bacteria that are resistant to other antibiotics.
Vancomycin:
Vancomycin is an antibiotic drug and it's used for the treatment of bacterial infections. It works by killing the bacteria that causes infection. The medicine was first developed in 1965 by Drs. Van Cleef & Arlet, a Belgium-based pharmaceutical company as a non-antibiotic drug to treat eye infections in patients suffering from diabetes or poor blood circulation.
Teicoplanin:
Teicoplanin is a form of antibiotic used to treat bacterial infections in the urinary tract, respiratory tract and female reproductive system. It works by killing the bacteria that causes infection. The drug has been approved for use in animals and is under clinical investigation for use in humans. However, it has not been approved as an animal feed additive yet.
The global market for Teicoplanin.
Application Insights:
The market is categorized based on the application as enterococcus treatment, staphylococcus aureus treatment, and others. The other applications include Clostridium difficile infection and methicillin-resistant Staphylococcus aureus (MRSA) treatment. The enterococcal infections segment dominated the overall market in terms of revenue share in 2017 owing to high product demand for treating various types ofEnteroccocia infections including bacteremia, endocarditis prophylaxis, meningitis/encephalitis prophylaxis among others.
The staphylococcal Aureus Treatment segment is expected to grow at lucrative CAGR during the forecast period due to increasing incidence rates of SARMAs across various regions coupled with rising awareness about these types of bacteria among healthcare professionals resulting in an increased number of prescriptions being written every year for glycopeptide antibiotics such as vancomycin.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a substantial number of pharmaceutical and biopharmaceutical companies involved in drug discovery and development. Moreover, increasing prevalence of multi-drug resistant tuberculosis is expected to boost product demand over the forecast period. Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure, improving economic conditions, and an increase in consumer disposable income levels. Furthermore, growing interest from major multinational players operating across this region will drive regional growth over the next eight years.
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the major growth drivers for the glycopeptide antibiotics market. Infectious diseases are caused by pathogenic microorganisms and can spread from one person to another, resulting in serious health complications. The growing prevalence of antibiotic-resistant infections is a major concern worldwide and has led to an increased demand for glycopeptide antibiotics.
- Rising awareness about antimicrobial resistance: There is a growing awareness among people about antimicrobial resistance (AMR) and its implications on human health. AMR occurs when bacteria become resistant to the effects of drugs, making them difficult to treat or cure. This has led to an increased demand for novel antibiotics such as glycopeptide antibiotics, which can effectively treat drug-resistant infections.
- Growing investment in R&D activities: Pharmaceutical companies are investing heavily in R&D activities to develop new and innovative drugs that can address the global problem of antibiotic resistance. This is expected to lead to the development of more effective glycopeptide antibiotics in the near future, thereby driving market growth."
Scope Of The Report
Report Attributes
Report Details
Report Title
Glycopeptide Antibiotics Market Research Report
By Type
Vancomycin, Teicoplanin, Bleomycin
By Application
Enterococcus Treatment, Staphylococcus Aureus Treatment
By Companies
ANI Pharmaceuticals, Hikma Pharmaceuticals plc, Aurobindo Pharma, Allergan, Theravance Biopharma, Shenwei Pharmaceutical, Zhejiang Hisun Pharmaceutical Co., Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Glycopeptide Antibiotics Market Report Segments:
The global Glycopeptide Antibiotics market is segmented on the basis of:
Types
Vancomycin, Teicoplanin, Bleomycin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Enterococcus Treatment, Staphylococcus Aureus Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ANI Pharmaceuticals
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- Allergan
- Theravance Biopharma
- Shenwei Pharmaceutical
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Lytix Biopharma
- Alvogen
- Eli Lilly and Company
Highlights of The Glycopeptide Antibiotics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Vancomycin
- Teicoplanin
- Bleomycin
- By Application:
- Enterococcus Treatment
- Staphylococcus Aureus Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glycopeptide Antibiotics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glycopeptide antibiotics are a type of antibiotic that work by stopping the growth of bacteria.
Some of the major companies in the glycopeptide antibiotics market are ANI Pharmaceuticals, Hikma Pharmaceuticals plc, Aurobindo Pharma, Allergan, Theravance Biopharma, Shenwei Pharmaceutical, Zhejiang Hisun Pharmaceutical Co., Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company.
The glycopeptide antibiotics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glycopeptide Antibiotics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Glycopeptide Antibiotics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Glycopeptide Antibiotics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Glycopeptide Antibiotics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Glycopeptide Antibiotics Market Size & Forecast, 2020-2028 4.5.1 Glycopeptide Antibiotics Market Size and Y-o-Y Growth 4.5.2 Glycopeptide Antibiotics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Vancomycin
5.2.2 Teicoplanin
5.2.3 Bleomycin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Enterococcus Treatment
6.2.2 Staphylococcus Aureus Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glycopeptide Antibiotics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glycopeptide Antibiotics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Vancomycin
9.6.2 Teicoplanin
9.6.3 Bleomycin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Enterococcus Treatment
9.10.2 Staphylococcus Aureus Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Vancomycin
10.6.2 Teicoplanin
10.6.3 Bleomycin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Enterococcus Treatment
10.10.2 Staphylococcus Aureus Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Vancomycin
11.6.2 Teicoplanin
11.6.3 Bleomycin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Enterococcus Treatment
11.10.2 Staphylococcus Aureus Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Vancomycin
12.6.2 Teicoplanin
12.6.3 Bleomycin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Enterococcus Treatment
12.10.2 Staphylococcus Aureus Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Vancomycin
13.6.2 Teicoplanin
13.6.3 Bleomycin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Enterococcus Treatment
13.10.2 Staphylococcus Aureus Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glycopeptide Antibiotics Market: Competitive Dashboard
14.2 Global Glycopeptide Antibiotics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ANI Pharmaceuticals
14.3.2 Hikma Pharmaceuticals plc
14.3.3 Aurobindo Pharma
14.3.4 Allergan
14.3.5 Theravance Biopharma
14.3.6 Shenwei Pharmaceutical
14.3.7 Zhejiang Hisun Pharmaceutical Co., Ltd.
14.3.8 Lytix Biopharma
14.3.9 Alvogen
14.3.10 Eli Lilly and Company